NEUROPHET

What NEUROPHET does

NEUROPHET (Neurophet Inc., KOSDAQ: 380550) is a South Korea-based medical AI company that develops and commercializes FDA-cleared and MFDS-approved software and neuromodulation devices for the full cycle of brain disease diagnosis and treatment. Founded in March 2016 as a spin-out from Gwangju Institute of Science and Technology (GIST), the company sells a portfolio organized into two product families: Neuro-Degeneration (Neurophet AQUA for MRI brain volumetry and white matter hyperintensity analysis, Neurophet AQUA AD and AQUA AD Plus for Alzheimer's ATNV biomarker analysis, Neurophet AQUA MS for multiple sclerosis lesion detection, Neurophet AQUA Pediatrics for infant brain MRI, Neurophet SCALE PET for multi-tracer PET quantification, and Neurophet SCALE MRI) and Neuro-Modulation (Neurophet tES LAB for transcranial electrical stimulation treatment planning and the Neurophet innk tDCS hardware device).

The underlying technology is a proprietary AI/deep learning imaging platform built around automatic brain MRI segmentation, atrophy quantification, multi-tracer PET SUVR computation (amyloid, tau, dopamine, FDG), Centiloid scale standardization (r=0.990 vs Klunk standard), ARIA monitoring via microbleed detection, and AI-generated patient-specific 3D head models for personalized tES electrode placement. The platform has accumulated three FDA 510(k) clearances and certifications across Korea, Japan, Europe, Singapore, and Thailand.

NEUROPHET generates revenue through multiple streams: one-time software licenses and an expanding subscription model for medical AI solutions sold to hospitals and academic medical centers; Imaging Core Lab (ICL) professional services for pharmaceutical clinical trials (notably AriBio's Phase 3 program in Korea, China, US, and Europe); hardware sales of the innk tDCS device; and QMS/design system consulting for SaMD developers. The company completed its KOSDAQ IPO in July 2025, has established a wholly owned US subsidiary, and serves customers across South Korea, the United States, Japan, Singapore, Australia, Spain, the UAE, and the UK, including the ALZ-NET network and major university hospitals such as University of Washington, Seoul National University Hospital, and Tokyo Metropolitan Health and Longevity Medical Center.

Name

NEUROPHET

Legal name

Neurophet Inc. (뉴로핏주식회사)

Website

https://neurophet.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

NEUROPHET is a KOSDAQ-listed South Korean medical AI company that develops FDA-cleared software and neuromodulation devices for brain MRI and PET imaging analysis, serving hospitals, academic medical centers, and pharmaceutical clinical trials across neurodegeneration (Alzheimer's, MS) and stroke rehabilitation markets globally.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Laboratories (621511), Other Computer Related Services (541519)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Neurology Telemedicine Platforms (HLALAGAC), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Medical Imaging AI (HDAAAEAH)

Keywords

• AI brain imaging software
• Medical imaging analysis
• Neurodegenerative disease diagnostics
• Transcranial electrical stimulation
• Clinical trial imaging services

Headquarters

HQ city

Gangneung

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Software Licensing: Software license sales of FDA 510(k)-cleared brain imaging analysis solutions (Neurophet AQUA, AQUA AD, AQUA AD Plus, AQUA MS, SCALE PET) to hospitals and medical institutions globally. Neurophet AQUA AD Plus is the third US regulatory milestone.
2. Subscription-based Software Services: Subscription-focused business model for medical AI solutions. Company is expanding subscription-centered operations following selection as supplier for 3 major Korean regional hub hospitals in June 2026.
3. Imaging Core Lab (ICL) Service: Professional clinical trial imaging analysis service for pharmaceutical and biotech companies. Offers full-cycle clinical research support including study design, image management, neuro-image analysis, and data management. Provides up to 80% faster analysis vs manual methods. Active engagements include AriBio AR1001 Phase 3 (Korea, China, US, Europe), Beyond Bio BEY2153 Phase 2, and NVP Healthcare NVP-NK4146 IIT.
4. Medical Device Hardware Sales: Hardware sales of innk (innk01-DW) non-invasive transcranial electrical stimulation device for stroke rehabilitation and depression treatment. Class 3 medical device cleared by Korea MFDS.
5. QMS and Design System Consulting: Quality Management System (QMS) consulting and design system consulting services for SaMD (Software as a Medical Device) companies. Covers ISO 13485, IEC 62304 compliance, documentation, training, and certification preparation. Backed by 15+ years of SaMD expertise.

Pricing tiers

Go-to-market motion5 records

Distribution channels6 records

Marketing channels6 records

Core offering

NEUROPHET develops and commercializes AI-based medical software that performs automated brain MRI and PET image analysis for neurodegenerative disease diagnosis and monitoring, including the Neurophet AQUA product family (brain volumetry, ATNV Alzheimer's biomarkers, multiple sclerosis lesion detection) and Neurophet SCALE PET (multi-tracer PET quantification with Centiloid Scale). The company also offers the Neurophet tES LAB treatment planning software, the Neurophet innk transcranial electrical stimulation medical device, and an Imaging Core Lab (ICL) clinical trial imaging analysis service for pharmaceutical and biotech customers, alongside QMS and design consulting for SaMD developers.

Product overview

Neurophet (뉴로핏) is a South Korea-based AI medical device company that offers a portfolio of FDA-cleared and MFDS-approved AI software solutions and neuromodulation devices for the full cycle of brain disease diagnosis and treatment. Its offering is structured as a platform-plus-modules architecture organized into two primary product families: (1) Neuro-Degeneration — Neurophet AQUA (MRI brain volumetry/atrophy analysis), Neurophet AQUA AD and the FDA-cleared Neurophet AQUA AD Plus (Alzheimer's ATNV biomarker analysis combining MRI and PET), Neurophet AQUA MS (multiple sclerosis lesion detection), Neurophet AQUA Pediatrics (infant brain MRI), and Neurophet SCALE PET (automated PET quantification with SUVR and Centiloid Scale); and (2) Neuro-Modulation — Neurophet tES LAB (AI-driven transcranial electrical stimulation treatment planning software) and the Neurophet innk (non-invasive tES medical device). Complementing the products, Neurophet offers services including the Imaging Core Lab (ICL) clinical trial imaging analysis service, Design System Consulting, and Quality Management System (QMS) Consulting for SaMD manufacturers. The portfolio collectively targets neurology, radiology, nuclear medicine, rehabilitation, and psychiatry clinicians and clinical researchers across South Korea, the U.S., Japan, Singapore, Thailand, and Europe.

Differentiator

Problem solved

Functional benefit

Brands

• Neurophet AQUA: AI-powered MRI brain volumetry software for analyzing brain atrophy and white matter degeneration to support diagnosis of degenerative brain diseases such as dementia, mild cognitive impairment, and small vessel disease. Cleared by Korea MFDS, U.S. FDA 510(k), Japan MHLW, European CE MDD, Singapore HSA, and Thailand TFDA.
• Neurophet AQUA AD
• Neurophet AQUA AD Plus
• Neurophet AQUA MS
• Neurophet AQUA Pediatrics
• Neurophet SCALE PET
• Neurophet SCALE MRI
• Neurophet tES LAB
• Neurophet innk

Products and services

• Neurophet AQUA AI-based brain MRI analysis software that automatically segments and quantifies brain atrophy and white matter hyperintensities (WMH) to support diagnosis of degenerative brain diseases including dementia, mild cognitive impairment, and small vessel disease. Provides both Asian and Western normative data for percentile-based evaluation.
• Neurophet AQUA AD AI-based comprehensive imaging biomarker solution for Alzheimer's disease that analyzes MRI and PET scans for early diagnosis, staging, treatment monitoring, and differential diagnosis. Performs integrated ATNV biomarker analysis (Amyloid, Tau, Neurodegeneration, Vascular) with longitudinal monitoring of anti-amyloid treatment effects and ARIA detection.
• Neurophet AQUA AD Plus Updated version of Neurophet AQUA AD and comprehensive brain imaging analysis solution to support Alzheimer's disease treatment decisions and ARIA monitoring. Received U.S. FDA 510(k) clearance as Neurophet's third U.S. regulatory milestone.
• Neurophet AQUA MS Multiple sclerosis lesion detection module of Neurophet AQUA, FDA 510(k)-cleared. AI algorithm detects MS lesions on MRI including Central Vein Sign and Paramagnetic Rim Lesions biomarkers.
• Neurophet SCALE PET Automated AI-based PET image quantitative analysis solution providing visualization and quantification of PET scans. Calculates SUVR and Centiloid Scale values across multiple PET tracers (amyloid, tau, dopamine, FDG), supports PET-MRI/PET-CT/PET-only inputs, with automated processing within 10 minutes.
• Neurophet SCALE MRI MRI module of the SCALE product line, MRI-based neurodegeneration quantification solution.
• Neurophet tES LAB AI-based treatment planning software that uses brain MRI to automatically generate patient-specific 3D head models (skin and bone) for simulating transcranial electrical stimulation (tDCS/tACS) effects. Supports electrode position optimization and personalized stimulation planning for clinical research.
• Neurophet innk (innk01-DW) Non-invasive transcranial electrical stimulation (tES) medical device (Korean MFDS Class 3) for functional recovery and rehabilitation of brain disease patients. Supports DC/AC/Sham current types with adjustable time and frequency parameters, designed for stroke rehabilitation and depression adjunct therapy. Pairs with the innk App.
• Neurophet Imaging Core Lab (ICL) Service Clinical imaging analysis service that supports end-to-end neuroimaging workflows for neurology clinical trials and drug development. Provides FDA-cleared AI-based MRI/PET quantification, biomarker analysis, study design support, image management, and data management. Serves neurodegenerative, demyelinating, cerebrovascular, and developmental disorder research, with up to 80% faster analysis vs manual methods.
• Quality Management System (QMS) Consulting Specialized consulting service for SaMD (Software as a Medical Device) QMS establishment and operations. Provides current state/GAP analysis, QMS strategy and roadmap, documentation and process building, training programs, and internal audit/certification preparation aligned with ISO 13485 and IEC 62304.
• Design System Consulting Consulting service for medical software design systems, supporting SaMD developers with UI/UX and design system practices aligned to medical device software standards.

Quantifiable outcome

• Up to 80% faster imaging analysis vs manual methods in clinical trials (ICL service)
• +4 more outcomes

Named customers22 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature11 records

Partnerships

27 partnerships are on record, tiered core, flagship and minor.

• VHIR (Vall d'Hebron Institut de Recerca, Spain)coreStrategic or Co-development Partner · 1 May 2026Joint research collaboration to develop and validate AI algorithms for detecting multiple sclerosis lesions based on MRI. Leverages VHIR's large-scale MRI datasets from over 1,000 clinically diagnosed MS patients to advance detection algorithms for Central Vein Sign and Paramagnetic Rim Lesions biomarkers. Aims to strengthen clinical reliability of Neurophet AQUA MS (FDA 510(k)-cleared). Announced May 2026.
• ALZ-NET (Alzheimer's Network for Treatment and Diagnostics)flagshipStrategic or Co-development Partner · 1 March 2026Signed Memorandum of Understanding (MOU) in March 2026 to provide imaging monitoring infrastructure for Alzheimer's therapies. ALZ-NET is sponsored by the Alzheimer's Association and managed by the American College of Radiology. The collaboration will deploy Neurophet's three FDA 510(k)-cleared brain imaging analysis tools — Neurophet AQUA, Neurophet SCALE PET, and Neurophet AQUA AD Plus — across ALZ-NET's participating medical centers and neuroimaging facilities to enhance ARIA (amyloid-related imaging abnormalities) monitoring as Alzheimer's treatments advance.
• The Florey Institute of Neuroscience and Mental Health (Australia)coreStrategic or Co-development Partner · 1 November 2025Research collaboration on 'Enhanced Dementia Diagnosis (EDD)' joint study to evaluate biomarkers for Alzheimer's disease diagnosis using Neurophet AQUA AI-driven brain neurodegeneration imaging software. Aims to improve high-precision dementia diagnosis in clinical settings. Announced November 2025.
• Modawina Medical (UAE)coreChannel Partner/ Reseller/ Distributor · 1 October 2025Exclusive distribution agreement signed October 2025 for UAE market.
• InRAD (International Alzheimer's and Other Dementia Registry Foundation)coreStrategic or Co-development Partner · 1 September 2025Signed MOU for global standard building in Alzheimer's disease and dementia registries. Announced September 2025.
• Hokuyaku Takeyama HoldingsminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as Japanese partner on Neurophet website partner page.
• LADO TechminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as partner on Neurophet website.
• QT InstrumentsminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as partner on Neurophet website.
• Doctor NetminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as partner on Neurophet website.
• Meridian HealthcareminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as partner on Neurophet website.
• HealthCare KonnectminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as partner on Neurophet website.
• AriBiocoreStrategic or Co-development Partner · 1 September 2024Joint development cooperation on next-generation Alzheimer's diagnostic platform (September 2024) and global Phase 3 clinical trial participation for joint research on dementia treatment (January 2024). AriBio's AR1001 is a leading Alzheimer's treatment in FDA-approved Phase 3 trial using Neurophet's SCALE PET for Centiloid Scale and SUVR analysis.
• ReadyCure (레디큐어)minorStrategic or Co-development Partner · 1 February 2024Business agreement for joint Alzheimer's disease treatment-related projects signed February 2024.
• Department of Radiology, University of WashingtonflagshipTechnology or Integration · 1 January 2024University of Washington Department of Radiology is listed as a key partner on the Neurophet website partner page. First US supply contract for Neurophet AQUA and Neurophet SCALE PET signed February 2026.
• Sun Yat-sen University HospitalminorStrategic or Co-development Partner · 1 January 2024Listed as partner on Neurophet website.
• FST (Fondooz)minorChannel Partner/ Reseller/ Distributor · 1 January 2024Listed as partner on Neurophet website.
• Konkuk University HospitalminorStrategic or Co-development Partner · 1 December 2023Brain disease imaging diagnostic technology research collaboration MOU signed December 2023.
• SK C&CminorStrategic or Co-development Partner · 1 November 2023Strategic business agreement for brain disease AI expansion signed November 2023.
• Roche & Plug and PlaycoreGTM or Marketing Partner · 1 August 2023Selected as participant in Roche & Plug and Play 'Startup Cresp APAC 2023' program (August 2023). Provides global startup visibility and ecosystem access.
• Createbo (크레아보, Japan)minorChannel Partner/ Reseller/ Distributor · 1 October 2022Sales partnership for Neurophet AQUA signed October 2022 in Japanese market.
• Hallym University Industry-Academic Cooperation FoundationminorStrategic or Co-development Partner · 1 September 2022Research cooperation MOU signed September 2022.
• Nanyang Technological University Singapore (NTU)flagshipStrategic or Co-development Partner · 1 September 2022Joint research cooperation agreement with NTU Singapore Dementia Research Center signed September 2022. Recognized for outstanding joint research September 2024. SEACURE Symposium hosted at NTU Singapore December 2025 with ~220 neurologists from 6 Southeast Asian countries.
• B. Braun KoreaminorStrategic or Co-development Partner · 1 October 2021R&D cooperation MOU signed October 2021.
• Medtronic KoreaminorStrategic or Co-development Partner · 1 May 2021R&D cooperation MOU signed May 2021.
• Medical Standard (메디칼스탠다드)minorChannel Partner/ Reseller/ Distributor · 1 November 2020Product sales partnership for Neurophet AQUA signed November 2020 in Korean market.
• BrainBox (UK)coreChannel Partner/ Reseller/ Distributor · 1 August 2019Distribution agreement signed August 2019 for Neurophet tES LAB products in the UK market.
• PhilipsminorGTM or Marketing Partner · 1 September 2018Selected for Philips global startup incubation program 'AI in Healthcare 2018' (September 2018).

Scale indicators12 records

Recent moves9 records

Direct peers

• BrainBox Solutions: US/UK AI MRI brain imaging company developing biomarkers for TBI, MS, and neurodegeneration. Existing Neurophet distribution partner (BrainBox UK for tES LAB) but also a competitor in the brain MRI biomarker space.
• icometrix: Belgium/US AI neuroimaging company offering FDA-cleared MS and dementia MRI quantification (icobrain ms, icobrain dm). Closely comparable to Neurophet AQUA, AQUA MS, and AQUA AD in target customers (radiology/neurology) and clinical use cases (MS, Alzheimer's).
• Pixyl: France-based AI neuroimaging company with FDA-cleared MS lesion and brain atrophy quantification (Pixyl.Neuro.MS). Directly competes with Neurophet AQUA MS in MS MRI and offers similar hospital-radiology workflow positioning.
• Cortechs.ai: US-based developer of AI MRI brain quantification software (NeuroQuant) for brain volume and lesion analysis. Directly overlaps Neurophet AQUA in MRI volumetry, MS lesion analysis, and ARIA monitoring; Neurophet's Head of Americas Business (Josh Cohen) joined Neurophet from Cortechs.ai.
• Qubiotech: Spanish AI neuroimaging company with Neurocloud platform for brain PET/MRI quantification, including amyloid, FDG and dopaminergic tracers. Closely comparable to Neurophet SCALE PET's multi-tracer PET SUVR and Centiloid quantification.

Emerging players

• Subtle Medical: US AI radiology company focused on accelerated MRI acquisition and PET denoising. Adjacent to Neurophet SCALE PET in AI-augmented PET imaging and shares the AI-imaging-for-Alzheimer's positioning.
• Viz.ai: US AI neurovascular imaging company with FDA-cleared stroke detection (Viz LVO, Viz ICH). Adjacent to Neurophet's stroke/tES portfolio (innk for stroke rehabilitation) and shares the AI neurology hospital sales motion.

Broad incumbents

• GE HealthCare: Global imaging OEM whose Edison platform includes AI neuroimaging apps and PET quantification. Large installed-base competitor that can bundle brain AI into enterprise imaging contracts. Former employer of Neurophet's CPO via GE Healthcare Korea Technology Center.
• Siemens Healthineers: Global medical imaging incumbent whose AI-Rad Companion and syngo.via include brain volumetry and PET quantification features. Broader portfolio competitor and also the prior employer of Neurophet's CPO, illustrating the talent flow between Neurophet and the incumbent.
• Philips: Global imaging OEM whose IntelliSpace AI and radiology workflows include brain quantification. Selected Neurophet for its 'AI in Healthcare 2018' startup program, but is also a broad-spectrum competitor in hospital imaging procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurophet

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEUROPHET